Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1973 1
1983 1
1984 1
1989 2
1990 1
1991 1
1995 2
1996 1
1997 5
1998 1
1999 2
2000 3
2001 4
2002 8
2003 3
2004 5
2005 3
2006 8
2007 4
2008 7
2009 8
2010 8
2011 5
2012 1
2013 9
2014 12
2015 7
2016 10
2017 14
2018 10
2019 9
2020 10
2021 20
2022 12
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for victories dt
Search for Victorien DT instead (2 results)
Antibiotics versus Appendectomy for Acute Appendicitis - Longer-Term Outcomes.
CODA Collaborative; Davidson GH, Flum DR, Monsell SE, Kao LS, Voldal EC, Heagerty PJ, Fannon E, Lavallee DC, Bizzell B, Lawrence SO, Comstock BA, Krishnadasan A, Winchell RJ, Self WH, Thompson CM, Farjah F, Park PK, Alam HB, Saltzman D, Moran GJ, Kaji AH, DeUgarte DA, Salzberg M, Ferrigno L, Mandell KA, Price TP, Siparsky N, Glaser J, Ayoung-Chee P, Chiang W, Victory J, Chung B, Carter DW, Kutcher ME, Jones A, Holihan J, Liang MK, Faine BA, Cuschieri J, Evans HL, Johnson J, Patton JH, Coleman N, Fischkoff K, Drake FT, Sanchez SE, Parsons C, Odom SR, Kessler LG, Talan DA. CODA Collaborative, et al. N Engl J Med. 2021 Dec 16;385(25):2395-2397. doi: 10.1056/NEJMc2116018. Epub 2021 Oct 25. N Engl J Med. 2021. PMID: 34694761 Clinical Trial. No abstract available.
Patient Factors Associated With Appendectomy Within 30 Days of Initiating Antibiotic Treatment for Appendicitis.
Writing Group for the CODA Collaborative; Monsell SE, Voldal EC, Davidson GH, Fischkoff K, Coleman N, Bizzell B, Price T, Narayan M, Siparsky N, Thompson CM, Ayoung-Chee P, Odom SR, Sanchez S, Drake FT, Johnson J, Cuschieri J, Evans HL, Liang MK, McGrane K, Hatch Q, Victory J, Wisler J, Salzberg M, Ferrigno L, Kaji A, DeUgarte DA, Gibbons MM, Alam HB, Scott J, Kao LS, Self WH, Winchell RJ, Villegas CM, Talan DA, Kessler LG, Lavallee DC, Krishnadasan A, Lawrence SO, Comstock B, Fannon E, Flum DR, Heagerty PJ. Writing Group for the CODA Collaborative, et al. JAMA Surg. 2022 Mar 1;157(3):e216900. doi: 10.1001/jamasurg.2021.6900. Epub 2022 Mar 9. JAMA Surg. 2022. PMID: 35019975 Free PMC article. Clinical Trial.
Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis.
Zakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Zakhari A, et al. Hum Reprod Update. 2021 Jan 4;27(1):96-107. doi: 10.1093/humupd/dmaa033. Hum Reprod Update. 2021. PMID: 33020832 Free PMC article.
BACKGROUND: Although surgery for endometriosis can improve pain and fertility, the risk of disease recurrence is high. There is little consensus regarding the benefit of medical therapy in preventing recurrence of endometriosis following surgery. ...We excluded from the fi …
BACKGROUND: Although surgery for endometriosis can improve pain and fertility, the risk of disease recurrence is high. There is little conse …
A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century.
Wang J, Zhao W, Zhang Z, Liu X, Xie T, Wang L, Xue Y, Zhang Y. Wang J, et al. Adv Mater. 2024 Apr;36(15):e2308915. doi: 10.1002/adma.202308915. Epub 2024 Jan 17. Adv Mater. 2024. PMID: 38229552
Nanomedicine integrates with other disciplines, establishing interdisciplinary platforms, in which drug delivery and nanoparticles remain focal points. Current research focuses on integrating nanomedicine and cell ferroptosis induction in cancer immunotherapy. The keyword …
Nanomedicine integrates with other disciplines, establishing interdisciplinary platforms, in which drug delivery and nanoparticles re …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and rece …
Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible …
Inflammation in Atherosclerosis-No Longer a Theory.
Libby P. Libby P. Clin Chem. 2021 Jan 8;67(1):131-142. doi: 10.1093/clinchem/hvaa275. Clin Chem. 2021. PMID: 33393629 Review.
Inflammatory status, determined by the biomarker C-reactive protein, can guide the allocation of statin therapy to individuals without elevated low-density lipoprotein (LDL) concentrations to prevent first ever adverse cardiovascular events. ...This long road from discover …
Inflammatory status, determined by the biomarker C-reactive protein, can guide the allocation of statin therapy to individuals withou …
Why haven't we solved the addiction crisis?
Blum K, Bowirrat A, Gomez LL, Downs BW, Bagchi D, Barh D, Modestino EJ, Baron D, McLaughlin T, Thanos P, Ceccanti M, Elman I, Badgaiyan RD, Dennen C, Gupta A, Braverman ER, Gold MS. Blum K, et al. J Neurol Sci. 2022 Nov 15;442:120404. doi: 10.1016/j.jns.2022.120404. Epub 2022 Sep 2. J Neurol Sci. 2022. PMID: 36084363 Review.
202 results